SNK01 for Moderate Alzheimer's Disease
This study is testing a new treatment called SNK01 for people with moderate Alzheimer's disease. SNK01 is a type of immunotherapy that uses your own natural killer (NK) cells, which are part of your immune system. Researchers want to see if SNK01 is safe and tolerable when given through an IV every three weeks for up to a year. They also want to see if it can improve cognitive assessment scores. You might be able to join if you are between 40 and 85 years old and have moderate Alzheimer's disease. The study is currently unclear on its status and plans to enroll 36 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment (SNK01 or a placebo). It plans to enroll 36 participants.
- What's involved
- SNK01 will be administered every 3 weeks for up to 1 year as an intravenous infusion. Adverse events will be assessed for 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for treatment-related adverse events for up to 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
At a glance
Conditions
Where it's being run
8 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with dose-limiting toxicity3 weeks
DLTs will be assessed by the review of labs, PE and AEs
- Maximum tolerated dose determination3 weeks
Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.01 Year
Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs
- Preliminary efficacy in cognitive assessment scores of CDR-SB1 Year
Measure changes in cognitive assessment of CDR-SB from baseline
- Preliminary efficacy in cognitive assessment scores of MMSE1 Year
Measure changes in cognitive assessment of MMSE from baseline
- Preliminary efficacy in cognitive assessment scores of NPI1 Year
Measure changes in cognitive assessment of NPI from baseline
- Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe1 Year
Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline
- Preliminary efficacy in cognitive assessment scores of ADAS-Cog1 Year
Measure changes in cognitive assessment of ADAS-Cog from baseline